Background. Patients with hypertension and myocardial hypertrophy may have signs and symptoms of myocardial ischemia in the absence of obstructive coronary disease. Prior investigations have demonstrated impaired coronary flow reserve and have led to speculation that microvascular dysfunction might contribute to ischemia in these patients. Experimental studies have shown that the endothelium, an important regulator of microvascular tone, can be damaged by hypertension and is dysfunctional in cardiomyopathy. We hypothesized that endothelium-dependent vasodilation is impaired in the coronary microvasculature of patients with hypertension and ventricular hypertrophy.
P atients with hypertension and ventricular hypertrophy frequently have signs and symptoms of myocardial ischemia in the absence of obstructive coronary disease. Contributing factors may include extrinsic vascular compression and inadequate microvascular growth relative to increased left ventricular mass.' Factors intrinsic to the coronary microvessel wall may also be important causes of ischemia in these patients. As the ventricle undergoes hypertrophy, the arterial media also thickens. Some investigators suggest that vasoconstrictor responses in these hypertrophied arteries are augmented.2 In addition, considerable data exist that are consistent with the notion that dysfunction of the microvascular endothelium may contribute to abnormalities of flow regulation in these patients. 34 Over the last decade, the central importance of the vascular endothelium to cardiovascular homeostasis has been increasingly appreciated. In addition to providing a nonthrombogenic surface for the arterial wall, the endothelium is a major regulator of vascular tone and growth. Furchgott and Zawadskis first demonstrated that endothelial cells release a potent vasodilator, endothelium-derived relaxing factor (EDRF), which produces relaxation of underlying vascular smooth muscle. The endothelium also releases potent vasoconstricting factors (endothelium-derived constricting factors, EDCFs), although their role in the human circulation remains undefined.67 Injury to the endothelium may produce alterations in the regulation of vascular tone and growth. Experimental hypertension is associated with morphological abnormalities of endothelial cells and with impaired endothelium-dependent relaxation to acetylcholine, ADP, and thrombin in large vessels. 8, 9 In the rabbit model, hypertension also impairs microvascular endothelial vasodilator function.'0 Treatment of hypertension tends to restore normal endothelium-dependent relaxations and reverse chronic vascular changes." In humans with essential hypertension, endothelium-mediated relaxation is impaired in the forearm circulation. '2,13 No studies have evaluated endothelium-mediated relaxation in the coronary microvessels of the hypertensive human. We investigated endothelium-mediated relaxation in the small coronary arteries of patients with hypertension and ventricular hypertrophy by evaluating coronary flow responses to the endothelium-dependent vasodilator acetylcholine and to the smooth muscle dilator adenosine.
Methods

Patient Population
Coronary microvascular responses were assessed in 10 patients with a history of hypertension (HTN) and compared with nine nonhypertensive control subjects. Patients were studied at Brigham and Women's Hospital (Boston), Emory University Hospital (Atlanta, Ga.), and Grady Memorial Hospital (Atlanta). One investigator was present for all studies (C.B.T.). Seven of nine control responses have been presented in a previous report. 14 The following clinical and laboratory information was collected from all patients: age, sex, history of smoking (defined as cigarette smoking within the 3 months before study), history of hypertension (defined as blood pressure elevation >140/90 mm Hg, requiring medication), total cholesterol level (mg/dl) at time of catheterization, family history of myocardial infarction (defined as first-degree relative at age <60 years), and history of insulin-dependent diabetes mellitus. 
Protocol
Statistical Analysis
Differences in clinical, hemodynamic, and echocardiographic parameters were compared using a twosample t test. Microvascular responses to drug infusions were compared using repeated-measures ANOVA. Statistical significance was assumed if the null hypothesis (two-tailed) could be rejected at the 0.05 probability level. All data are expressed as mean±SEM.
Results
Clinical Data
Ten HTN patients were compared with nine nonhypertensive control patients (Table 1) . Nine HTN patients and all nonhypertensive control subjects were undergoing diagnostic catheterization for evaluation of 
Hemodynamic Responses
Heart rate and systemic arterial pressure did not vary significantly during evaluation of coronary flow responses in either patient group. In HTN patients, heart rate was 71±3 beats per minute at baseline, 68-±-4 beats per minute at peak acetylcholine, and 70±3 beats per minute at peak adenosine (all p=NS). In nonhypertensive control subjects, heart rate was 66±4 beats per minute at baseline, 66+4 beats per minute at peak acetylcholine, and 64±4 beats per minute at peak adenosine (allp=NS). In HTN patients, mean systemic arterial pressure was 114±3 mm Hg at baseline, 115±3 mm Hg at peak acetylcholine, and 119±4 mm Hg at peak adenosine (allp=NS). In nonhypertensive control subjects, systemic arterial pressure was 93±5 mm Hg at baseline, 93±7 mm Hg at peak acetylcholine, and 103±8 mm Hg at peak adenosine (all p=NS).
Coronary Microvascular Flow Responses
Acetylcholine. In HTN patients, coronary flow responses to the endothelium-dependent vasodilator acetylcholine were markedly impaired (Figure 2) . In HTN patients, coronary blood flow increased -4±4%, -3±10%, and 32±25% in response to acetylcholine 10-8 M, 10-7 M, and 106 M, respectively. In nonhypertensive control subjects, coronary blood flow increased 25±13%, 106±34%, and 192±39% in response to acetylcholine 10-8 M, 10-7 M, and 10-6 M, respectively (p=0.003).
Adenosine. Coronary flow responses to the endothelium-independent vasodilator adenosine were similar in HTN patients and nonhypertensive control subjects (Figure 3) . In HTN patients, coronary blood flow increased 82±26%, 417±115%, and 465±93% in response to adenosine 10-6 M, 10`M, and 10-4 M, respectively. In nonhypertensive control subjects, coronary blood flow increased 170±32%, 286±33%, and 439±41% in response to adenosine 10-6 M, 10`M, and
10-4 M, respectively (p=NS).
Endothelium-dependent flow response. To examine the endothelium-dependent component of the maximal vasodilator response, each patient's flow response to the endothelium-dependent vasodilator acetylcholine was normalized by his/her maximal flow response to aden- osine. The endothelium-dependent flow response was markedly impaired in HTN patients (Figure 4 ). The proportion of coronary flow reserve attributable to endothelium-dependent dilation (obtained from acetylcholine dose/peak adenosine flow response) was -2±1%, -2+4%, and 7±8% to serial doses of acetylcholine in HTN patients. In nonhypertensive control subjects, the proportion of coronary flow reserve attributable to endothelium-dependent dilation was 8±5%, 28±10%, and 48±9% to serial doses of acetylcholine (p=0.008).
Correlates of the microvascular response to acetylcholine in HTNpatients. To address the relative importance of the effects of hypertension versus ventricular hypertrophy on the coronary microvascular endothelium in HTN patients, we compared the peak response to acetylcholine with left ventricular posterior wall thickness and arterial pressure at time of catheterization (systolic, diastolic, and mean). An were preserved, which probably reflects the mild degree of ventricular hypertrophy.
Endothelium-Derived Relaxing and Constricting Factors
Over the last decade, the endothelium has become recognized as a major regulator of vascular tone and growth. Several landmark studies have led to this appreciation of the importance of the endothelium. Furchgott and Zawadskis demonstrated that when appropriately stimulated, endothelial cells release EDRF, a potent vasodilator (later characterized at least in part as nitric oxide'9) that produces relaxation of underlying vascular smooth muscle. This endogenous vasodilator is released in response to many stimuli including acetylcholine, substance P, and bradykinin.20 Endothelium-dependent relaxation, presumably caused by EDRF, has been demonstrated in both large2' and small'4 coronary arteries of humans. Recent studies have described a group of at least three EDCFs. EDCF1 (blocked by calcium channel antagonists)7 and EDCF2 (blocked by cyclooxygenase inhibitors)22'23 have been described in animal models of disease but currently have no known role in the human circulation. Endothelin, a 21-amino acid peptide,6 is the only EDCF known to be produced in and released from human endothelium.
Vascular Abnormalities in Hypertension
Hypertension and myocardial hypertrophy have profound effects on the vasculature. Hypertension accelerates the atherosclerotic process, especially in the presence of concomitant coronary risk factors.24 Chronic hypertension produces marked intimal hyperplasia and medial thickening of the vessel wall. 25 In humans, early hypertension (without ventricular hypertrophy) is associated with augmented coronary microvascular responsiveness to vasoconstrictor stimuli. 26 In the severely hypertrophied heart, the ability of the coronary circulation to allow normal increases in flow in response to intense dilator stimuli is impaired. 
Conclusions
This study demonstrates that endothelium-mediated relaxation is impaired in the coronary microvessels of patients with hypertension and mild ventricular hypertrophy. These findings may have important implications regarding altered control of myocardial perfusion in hypertensive heart disease.
